MX2022014756A - Cepas vivas atenuadas de fiebre aftosa modificadas por desoptimizacion y usos de las mismas. - Google Patents

Cepas vivas atenuadas de fiebre aftosa modificadas por desoptimizacion y usos de las mismas.

Info

Publication number
MX2022014756A
MX2022014756A MX2022014756A MX2022014756A MX2022014756A MX 2022014756 A MX2022014756 A MX 2022014756A MX 2022014756 A MX2022014756 A MX 2022014756A MX 2022014756 A MX2022014756 A MX 2022014756A MX 2022014756 A MX2022014756 A MX 2022014756A
Authority
MX
Mexico
Prior art keywords
foot
deoptimization
mouth disease
live attenuated
attenuated strains
Prior art date
Application number
MX2022014756A
Other languages
English (en)
Inventor
Steffen Mueller
Aida E Rieder
Los Santos Teresa B De
Segundo Fayna C Diaz-San
Anna Kloc
John R Coleman
Gisselle N Medina
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of MX2022014756A publication Critical patent/MX2022014756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción describe virus de fiebre aftosa desoptimizados y su uso para el tratamiento profiláctico y terapéutico de sujetos mamíferos. Los virus recombinantes proporcionados en la presente incluyen alteraciones en varias regiones genómicas, así como marcadores de diferenciación infectados de animales vacunados (DIVA, por sus siglas en inglés).
MX2022014756A 2020-05-27 2021-05-26 Cepas vivas atenuadas de fiebre aftosa modificadas por desoptimizacion y usos de las mismas. MX2022014756A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030431P 2020-05-27 2020-05-27
PCT/US2021/034282 WO2021242879A1 (en) 2020-05-27 2021-05-26 Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
US17/330,545 US11793870B2 (en) 2020-05-27 2021-05-26 Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof

Publications (1)

Publication Number Publication Date
MX2022014756A true MX2022014756A (es) 2023-05-16

Family

ID=78722735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014756A MX2022014756A (es) 2020-05-27 2021-05-26 Cepas vivas atenuadas de fiebre aftosa modificadas por desoptimizacion y usos de las mismas.

Country Status (10)

Country Link
US (1) US11793870B2 (es)
AU (1) AU2021282245A1 (es)
BR (1) BR112022024067A2 (es)
CA (1) CA3185141A1 (es)
CL (1) CL2022003345A1 (es)
IL (1) IL298481A (es)
MX (1) MX2022014756A (es)
PE (1) PE20230833A1 (es)
WO (1) WO2021242879A1 (es)
ZA (1) ZA202213497B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005294129B2 (en) * 2004-10-08 2010-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonymous codons
HRP20181319T4 (hr) * 2007-03-30 2024-02-16 The Research Foundation Of The State University Of New York Oslabljeni virusi koji su korisni kao cjepiva
BR112012023852B1 (pt) 2010-03-12 2020-11-10 Biolex Therapeutics vacinas recombinantes do vírus da língua azul e usos das mesmas
US8765141B2 (en) 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
SI3244920T1 (sl) * 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
US10953085B2 (en) * 2017-05-09 2021-03-23 Lawrence Livermore National Security, Llc Genetically engineered Foot and Mouth Disease Virus and related proteins, polynucleotides, compositions, methods and systems

Also Published As

Publication number Publication date
PE20230833A1 (es) 2023-05-19
BR112022024067A2 (pt) 2023-04-25
US20210401967A1 (en) 2021-12-30
CA3185141A1 (en) 2021-12-02
CL2022003345A1 (es) 2023-05-19
ZA202213497B (en) 2023-08-30
IL298481A (en) 2023-01-01
US11793870B2 (en) 2023-10-24
WO2021242879A1 (en) 2021-12-02
AU2021282245A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
Zhou et al. Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations
WO2016198531A3 (en) Hpv vaccines
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
DE60314823D1 (de) Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
AR093185A1 (es) Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles
CL2023000629A1 (es) Partículas virales modificadas y usos de estas
Zhang et al. Human infection with ORF virus from goats in China, 2012
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
MX2020006662A (es) Vacuna combinada intradermica contra mycoplasma y circovirus porcino.
ZA202213497B (en) Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
IN2014DN08927A (es)
MX363264B (es) Vectores de vacuna recombinante de herpesvirus bovino 1 (bohv-1) con baja virulencia.
Malmarugan et al. Diagnosis and therapeutic management of goat pox in ovines
GEP20227432B (en) Therapy of high-risk human papillomavirus infections
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
Libeau et al. Development of vaccines against peste des petits ruminants: CIRAD’s achievements and future challenges
MX2021015494A (es) Profarmacos de quinazolina para el tratamiento de infecciones viricas y otras enfermedades.
Kumar et al. Insights into the Mechanisms of action of Chloroquine and Hydroxychloroquine and its use in COVID-19 for chemoprophylaxis